Walleye Capital’s AtriCure ATRC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-10,588
Closed -$322K 5567
2024
Q1
$322K Sell
10,588
-102,493
-91% -$3.43M ﹤0.01% 3604
2023
Q4
$4.04M Buy
+113,081
New +$4.21M 0.01% 1239
2023
Q2
Sell
-5,385
Closed -$223K 4298
2023
Q1
$223K Buy
+5,385
New +$223K ﹤0.01% 2384
2022
Q4
Sell
-8,807
Closed -$344K 3169
2022
Q3
$344K Buy
+8,807
New +$403K 0.01% 1733
2022
Q1
Sell
-4,318
Closed -$300K 2279
2021
Q4
$300K Sell
4,318
-315
-7% -$22.9K 0.01% 1248
2021
Q3
$322 Buy
+4,633
New +$357K 0.01% 974
2020
Q4
Sell
-9,505
Closed -$379K 935
2020
Q3
$379K Buy
+9,505
New +$403K 0.04% 448

Other funds holding ATRC

Walleye Capital's ATRC Position: Q2 2024 in Review

Walleye Capital sold out of AtriCure (ATRC) in Q2 2024, closing a stake of 10,588 shares — an estimated $322K sold.

Walleye Capital first reported a position in ATRC in Q3 2020 and held it in 7 quarters. The position peaked at $4.04M in Q4 2023. 197 funds tracked by Wall St. Rank hold ATRC as of Q2 2024.

  • Walleye Capital reported no remaining AtriCure position as of Q2 2024 after selling out during the quarter.
  • Walleye Capital sold 10,588 AtriCure shares in Q2 2024, an estimated $322K.
  • Walleye Capital first reported a position in AtriCure in Q3 2020 and held it in 7 quarters.
  • Walleye Capital's AtriCure position peaked at $4.04M in Q4 2023.
  • 197 funds tracked by Wall St. Rank held AtriCure as of Q2 2024.

Based on Walleye Capital's 13F filing for Q2 2024, filed 14 Aug 2024.